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Background
The Global Hepatitis Health Sector Strategy is aiming for “elimination of viral hepatitis as a
public health threat” by 2030 [1], while enhanced elimination efforts for hepatitis are also pro-
moted under the broader remit of global Sustainable Development Goals (SDGs) [2]. This is
an enormous challenge for hepatitis B virus (HBV) given the estimated global burden of 260
million chronic carriers, of whom the majority are unaware of their infection [3] (Fig 1).
We here present HBV within the framework for neglected tropical diseases (NTDs) [4] in
order to highlight the ways in which HBVmeets NTD criteria and to discuss the ways in
which the NTDmanagement paradigm could be used to strengthen a unified global approach
to HBV elimination [5]. The major burden of morbidity and mortality from HBV is now
borne by tropical and subtropical countries [6]. Many African populations epitomize specific
vulnerability to HBV [7], so we here focus particular attention on Africa, both through focus
on the existing published literature and through presentation of a unique data set of opinion
and experience (see S1 Supporting Information). However, the themes we represent are trans-
ferable to other low- and middle-income settings and are relevant on the global stage.
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Current strategies for HBV control
Robust preventive vaccines have been rolled out in Africa since 1995 as a component of the
Expanded Programme on Immunization (EPI). Traditionally, most vaccine campaigns have
relied upon monovalent HBV vaccines (for summary, see https://doi.org/10.6084/m9.figshare.
5242303.v1). For adults with chronic infection and evidence of ongoing liver damage, a daily
dose of suppressive antiviral therapy using nucleot(s)ide analogues (Table 1) is successful at
mediating viremic suppression in the majority of cases, reducing complications and diminish-
ing spread. Antiviral therapy does not commonly result in cure, due to the persistence of DNA
in the hepatocyte nucleus, in the form of both cccDNA and integrated HBV DNA, but inter-
feron (IFN)-based therapy can increase rates of clearance.
Prevention of mother to child transmission (PMTCT) can be improved through a combina-
tion of routine antenatal screening, antiviral drugs during the latter stages of pregnancy, and
HBV vaccination to the baby starting at birth. Where resources permit, HBV immunoglobulin
(HBIG) can further reduce the risk of vertical transmission.
Fig 1. The hepatitis B virus (HBV) cascade. Diagrammatic representation of the total burden of HBV infection and the subsets of
individuals who are diagnosed (orange), linked to care (green), engaged with care (blue), on treatment (light purple), and have suppressed
viremia (dark purple). An estimate of the proportion of cases undiagnosed versus diagnosed (91% versus 9%, respectively) is based on the
WHO fact sheet [3]. The proportion who flow from each pool to the next is otherwise represented by a question mark, as these numbers are
not represented by robust data.
https://doi.org/10.1371/journal.pntd.0005842.g001
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Table 1. Drug therapy used to treat HBV. Costing is based on the International Medical Products Price Guide: http://mshpriceguide.org/en (data accessed May 2017. Price for lamivu-
dine (3TC)—South Africa Department of Health; Price for tenofovir (TDF)—Supply Chain Management Project; price for HBV immunoglobulin (HBIG)—Sudan Medicins Sans Fron-
tieres). WHO essential medicines: http://who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1.
Drug name Drug class Potency
against
HBV
Resistance Severe adverse
effects
Safe in
pregnancy?
Use in children Use as part
of
combined
ART?
WHO
“essential
medicine”
Monitoring Cost
(International
Medical
Products Price
Guide)
Tenofovir
(TDF)
Nucleotide
reverse
transcriptase
inhibitor
+ Rare Lactic acidosis,
hepatitis, renal
injury, bone
demineralization
Yes !12 years for
HBV**
Yes Yes LFTs, renal
function
US$3.91/month
Entecavir
(ETV)
Nucleoside
reverse
transcriptase
inhibitor
++ 10% at 3
years.
Increased in
3TC resistance
Lactic acidosis,
steatosis
Not known From age 2
years
No Yes LFTs, FBC Not listed
Lamivudine
(3TC)
Nucleoside
reverse
transcriptase
inhibitor
+
(potentially
limited by
resistance)
50% at 3 years.
Best-
recognized
mutations are
in YMDD motif
in viral
polymerase.
Lactic acidosis,
hepatomegaly and
steatosis,
pancreatitis
Yes From birth Yes Yes LFTs, FBC US$1.43/month
Interferon
(IFN)
Biologic
response
modifier
+ (genotype
dependent)
No Anorexia, diarrhea,
flu-like symptoms,
neurotoxicity,
seizures,
hepatotoxicity
No Not
recommended
in children (!18
years only)***
N/A Yes LFTs, FBC,
TFTs
Not listed
HBV
immuno-
globulin
(HBIG) for
prophylaxis
Biologic
response
modifier
++ N/A Abdominal pain,
buccal ulceration,
chest pain
Yes From birth N/A No N/A US$38.02/dose
Abbreviations: ART, antiretroviral therapy (for HIV infection); FBC, full blood count; HBV, hepatitis B virus; LFT, liver function test; N/A, nonapplicable; TFT, thyroid function test;
YMDD, tyrosine-methionine-aspartic acid-aspartic acid motif.
*Potency against HBV is defined as + or ++ to differentiate between agents with lower and higher suppressive capacity, respectively.
** British National Formulary (https://www.bnf.org/) states tenofovir can be prescribed for HIV in infants !2 years, but data for HBV treatment are lacking.
*** British National Formulary (https://www.bnf.org/) states Peg-interferon-alpha can be prescribed for chronic hepatitis C virus (HCV) in infants !5 years, but data for HBV treatment
are lacking. https://www.medicinescomplete.com/mc/bnfc/current/
https://doi.org/10.1371/journal.pntd.0005842.t001
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Despite the efficacy of these strategies in managing or preventing individual cases, these
interventions do not currently offer a route to global HBV eradication, due to a shortage of
investment and resources, the large pool of undiagnosed cases, lack of routine diagnostic
screening, the high cost of IFN and HBIG, the lack of a curative therapy, substantial gaps in
drug and vaccine coverage, and the potential for increasing drug resistance [8].
Application of NTD criteria to HBV
We have applied the WHO criteria for NTDs to HBV [4] and refer to case studies and experi-
ence from our own clinical practice (S1 Supporting Information) to illustrate how HBV in
Africa fulfills NTD criteria. Some of the factors underpinning the neglect of this infection are
summarized in Table 2.
NTDs “primarily affect populations living in tropical and subtropical
areas”
Although HBV is endemic globally, the bulk of morbidity and mortality is now borne by low-/
middle-income countries in tropical and subtropical regions [6,13]. In Africa, many popula-
tions are particularly vulnerable due to coendemic HIV infection and other coinfections, host
and viral genetic factors, poverty, and lack of education and infrastructure [7]. In this setting,
HBV has been eclipsed by the more acute and tangible health crisis of human immunodefi-
ciency virus (HIV); only now in the era of antiretroviral therapy (ART) is it reemerging as a vis-
ible threat [S1 Supporting Information; case 2]. One illustration of this shift is the increase in
deaths from HBV-related liver cancer over time that contrasts a reduction in AIDS deaths [14].
NTDs “disproportionately affect populations living in poverty and
cause. . .morbidity and mortality, including stigma and discrimination”
HBV is part of a cycle of poverty, with a high burden of morbidity and mortality in young
adults. The economic burden on individual families can be particularly catastrophic in low-
and middle-income settings [15], although robust data are lacking for Africa. In resource-poor
settings, lack of education and scarce healthcare resources impinge on successful diagnosis
and monitoring as well as failure to control symptoms where relevant. Stigma and
Table 2. Summary of factors potentially contributing to the neglect of investment in hepatitis B virus (HBV) clinical care, research, advocacy, and
education.
Factors contributing to HBV neglect
• Stigma and discrimination leading to lack of patient voice (S1 Supporting Information; cases 5, 6, 7) [9].
• Silent infection, which may never be diagnosed and is not apparent to onlookers (contributes to large pool of undiagnosed infection).
• Poverty, leading to lack of patient voice, lack of public profile, and underrepresentation (S1 Supporting Information; cases 4, 5, 7).
• Complacency that ongoing deployment of existing resources and approaches (e.g., suppressive antiviral therapy and vaccination) is sufficient to bring
about elimination [10].
• High burden in low-/middle-income countries [6], where investment is not a priority.
• Lack of public/media representation; no “high profile” cases.
• HBV is “eclipsed” by higher profile infections such as HIV and malaria.
• Poor education and knowledge among patients, the public, and healthcare workers (S1 Supporting Information; cases 6, 8, 9) including
underrecognition of the global burden of infection.
• Lack of existing investment [11,12] contributing to a cycle of underinvestment (Fig 2).
• Lack of development of infrastructure through which to provide education, prevention, diagnosis, and treatment and as a way to collect robust data.
• Poor-quality data (poor understanding of epidemiology and risk factors, little recognition of the impact of stigma, lack of assessment regarding feasibility
of interventions, etc.). (S1 Supporting Information; cases 7, 8)
• Lack of major dedicated funding agencies.
https://doi.org/10.1371/journal.pntd.0005842.t002
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discrimination are often invisible but can be potent and highly relevant challenges to the suc-
cess of scaling up interventions for prevention, diagnosis, and treatment [9] [S1 Supporting
Information; cases 1, 4, 5, 6, 7, 9].
NTDs are “immediately amenable to broad control, elimination, or
eradication by applying. . .public health strategies”
We already have an armamentarium of strategies with which to tackle HBV prevention and
treatment (Fig 3). In order to be widely and robustly deployed, these approaches should inter-
link with existing resources and infrastructure wherever possible [S1 Supporting Information;
case 2].
NTDs are “relatively neglected by research—i.e., resource allocation is
not commensurate with the magnitude of the problem”
Compared with other blood-borne viruses, namely, HIV and hepatitis C virus, which infect
substantially lower numbers [7], HBV has attracted far fewer research resources, and this gap
Fig 2. Resource gap in research funding allocations and academic publications for hepatitis B virus (HBV), hepatitis C virus
(HCV), HIV, and malaria. Panels A/C: funding data from the United States National Institutes for Health (NIH) estimated funding for
research, condition, and disease categories 2013–2018 (*projected figures for 2017 and 2018), available at https://report.nih.gov/
categorical_spending.aspx, downloaded June 2017. For the projected funding allocation for 2018, HCV will receive 2.3-fold HBV funding,
malaria 4.8-fold, and HIV 66.8-fold. Research into “malaria” and “malaria vaccine” are subdivided in the source data set but have been
pooled in this graphic. Panels B/D: We recorded the number of publications listed on NCBI PubMed based on the search terms “HIV,”
“HBV,” “HCV,” and “malaria” for each year from 2007–2016. Example search string for HBV publications in 2016: (HBV[Title]) AND ("2016/
01/01"[Date—Publication]: "2016/12/31"[Date—Publication]). Data are represented as absolute numbers (panels A and B) and the
proportion of the whole (panels C and D). For hepatitis delta virus (HDV), funding allocation data are not available, and we identified 25
publications/year (range 7–23).
https://doi.org/10.1371/journal.pntd.0005842.g002
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may actually be widening over time [11,12] (Fig 2). A recent report of infectious diseases
research investment in United Kingdom institutions documents that 0.7% of total expenditure
is for HBV, compared to 3.0% for HCV, 13.9% for malaria, and 17.5% for HIV [12]. HBVmor-
tality (887,000 deaths/year [3]) is now twice that of malaria (429,000 deaths/year [16]), but
malaria receives nearly 5-fold more funding (Fig 2). Hepatitis delta virus (HDV), a copassen-
ger with HBV, can drive aggressive liver disease but is almost completely overlooked in terms
of resource allocation. Moreover, development of clinical programs for hepatitis testing and
treatment are fragmented in comparison to the progressive infrastructure that has emerged to
tackle HIV [S1 Supporting Information; case 7].
Recommendations based on NTD framework
Even for an organism that is not officially recognized as an NTD, there is much to be learnt
from the NTD paradigm that could accelerate progress in tackling HBV. The ethos of combin-
ing several public health strategies and integrating care for different diseases is captured by the
approach advocated for NTDs [4] and is also a helpful strategy for HBV. Particularly in the
African subcontinent, where other NTDmodels have had significant impact [17], using this
Fig 3. A package of interventions to move towards elimination of hepatitis B virus (HBV) infection as a public health threat.
Suggested measures are aligned with WHO interventions for neglected tropical diseases (NTDs).
https://doi.org/10.1371/journal.pntd.0005842.g003
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framework for HBV could promote awareness, leverage advocacy and resources, and promote
integration of HBV prevention and treatment into existing HIV infrastructure [5].
In the following section, we use suggested interventions for NTDs to discuss briefly how
these are pertinent to reducing—and ultimately eliminating—HBV infection as a public health
threat.
“Intensified case management”
Based on the significant numbers of individuals lost at every step of the “cascade” from diagno-
sis through to successful treatment and prevention (Fig 1), enhanced efforts are needed to pro-
mote linkage through care pathways. Enhanced HBV testing is crucial to facilitate entry into
clinical care, allowing treatment to reduce the risk of onward spread, including underpinning
PMTCT [S1 Supporting Information; case 8]. Initially, this may rely on using existing diagnos-
tic platforms (based on serology), but investment is required in developing and rolling out
new approaches, including molecular testing strategies that are more sensitive, provide
enhanced data (e.g., detection of drug resistance), and are fast enough to enable point-of-care
testing. This can often be transferred from technology that has been initially developed for the
diagnosis of other diseases. Definitive curative therapy for HBV remains a crucial aspiration,
as elimination using existing strategies is not realistic during the time frames set by SDGs [10].
Specifically, a therapeutic vaccine harnessing successful immune responses to boost immune
clearance would provide a huge leap forward in tackling the existing burden of chronic infec-
tion [18].
The role and significance of stigma associated with HBV infection in Africa is largely unre-
ported in the literature. However, individual testimony leaves no doubt that this is a significant
barrier to diagnosis and clinical care [S1 Supporting Information; cases 5, 6]. Gaining a better
understanding of the extent and nature of stigma and discrimination in different populations
is a crucial first step, in parallel with enhanced efforts to educate patients, health care workers,
and the public.
“Preventive chemotherapy”
Although antiviral therapy for HBV is generally regarded as treatment rather than prevention,
in the majority of cases, it renders individuals aviremic, preventing onward transmission.
Antiviral therapy for HBV (Table 1) should be made accessible, ideally capitalizing on the sup-
ply chains and distribution infrastructure that have been developed for HIV (and/or other
prevalent infections, such as tuberculosis and malaria) [5]. Research efforts are still required to
identify prognostic factors that predict differential response to therapy and allow tailoring of
care.
PMTCT can progressively become a realistic goal by expanding access to antenatal diagnos-
tics, simple treatment interventions such as maternal tenofovir during trimester 3, and HBV
vaccination for all babies, with the first dose delivered at birth [8]. Vaccination remains a
cornerstone of prevention, but more work is needed to investigate the most effective catch-
up immunization strategies to reduce the burden of HBV infection at a population level
[S1 Supporting Information; cases 3, 4, 8].
“Sanitation and hygiene”
Although this category of interventions is conventionally applied to reducing food- and water-
borne infections, we here broaden our interpretation to include other aspects of prophylaxis.
Safety and security of medical supplies has increasingly improved to reduce nosocomial trans-
mission of blood-borne viruses over recent decades [S1 Supporting Information; case 3].
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However, sterile practices need to be more widely promoted and guaranteed to assure the
safety of other procedures such as scarification, tattoos, piercings, and circumcision that may
occur in community settings. Provision of condoms alongside education regarding safe sex,
particularly for high-risk groups such as sex workers and men who have sex with men, is
another important strategy for prevention.
Conclusions
Elimination of HBV infection has gained status within international health and development
agendas but is a complex clinical and public health challenge that currently lacks proportionate
multilateral commitment from pharma, government, commissioners, funders, and the
research community. The many parallels with other NTDs are clearly exemplified by vulnera-
ble populations of the African subcontinent. By viewing HBV—as well as its partner in coin-
fection, HDV—within the NTD framework, we can improve approaches to reducing the
burden of disease and move towards eventual elimination.
Supporting information
S1 Supporting Information. This document contains supporting information to corrobo-
rate the view that hepatitis B virus (HBV) can helpfully be represented within the frame-
work set out for neglected tropical diseases (NTDs) by the World Health Organization
(WHO) [1]. This is in line with aims stated within Sustainable Development Goals (SDGs) [2].
Complementary evidence gathered from patients, researchers, and healthcare workers from
different locations in Africa illustrates the ways in which HBV infection meets the criteria for
NTDs. These scenarios (designated cases 1 to 9 and presented geographically in order from
south to north) contribute important insights into how the NTD paradigm can be helpful in
informing strategies to improve diagnosis, treatment, and prevention of HBV infection, with
the ultimate goal of eliminating infection as a public health threat.
(PDF)
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